Revenue segments as reported by the company.

Consumer Health

Pharmaceutical

Medical Devices

Innovative Medicine

MedTech

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, marketing and administrative expenses

Research and development expense

In-process research and development

Interest expense

Other expense

Restructuring

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Johnson & Johnson

Band-Aid is a brand name of American pharmaceutical and medical devices giant Johnson & Johnson's line of adhesive bandages.

Band-Aid

Johnson's Baby is an American brand of baby cosmetics and skin care products owned by Johnson & Johnson. The brand dates back to 1893 when Johnson's Baby Powder was introduced. Product line consists of baby powder, shampoos, body lotions, massage oil, shower gels and baby wipes. The brand has reputation for making baby products that are "exceptionally pure and safe" since at least the 1980s.

Johnson's Baby

Aveeno is a brand of skin care and hair care products in the United States owned by American consumer goods and pharmaceutical company Johnson & Johnson. Aveeno was founded in 1945, and its first product was their Soothing Bath Treatment. The active ingredient in all Aveeno products are colloidal oats and/or oat extracts - Avenanthramides, which have been branded as "active naturals". Aveeno offers products to treat skin conditions such as eczema, psoriasis, urushiol-induced contact dermatitis, pruritus ani, chickenpox, hives, and sunburn.

Aveeno

Neutrogena is an American brand of skin care, hair care and cosmetics, that is headquartered in Los Angeles, California. According to product advertising at their website, Neutrogena products are distributed in more than 70 countries. Neutrogena was founded in 1930 by Emanuel Stolaroff, and was originally a cosmetics company named Natone. It is now part of the US-based Johnson & Johnson conglomerate, which bought the independent company in 1994.

Neutrogena

Clean & Clear is a line of dermatology products owned by Johnson & Johnson.

Clean & Clear

Listerine is a brand of antiseptic mouthwash product. It is promoted with the slogan "Kills germs that cause bad breath". Named after Joseph Lister, a pioneer of antiseptic surgery, Listerine was developed in 1879 by Joseph Lawrence, a chemist in St. Louis, Missouri.

Listerine

Acuvue (from "Accurate view") is a brand of disposable contact lenses made by Jacksonville-based Vistakon, a subsidiary of Johnson & Johnson (J&J).

Acuvue

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Johnson & Johnson reports solid Q4 earnings, eyes $60B Pharma revenue

Johnson & Johnson's Q4 2022 showed steady operational growth and strong financial performance. The company aims for continued growth in Pharmaceuticals, focusing on key products and pipeline advancements. Challenges include managing costs, addressing sales declines, and navigating market uncertainties.

Johnson & Johnson reports resilient Q1 performance amidst challenges

Johnson & Johnson's Q1 2023 performance reflects resilience and growth across key segments despite short-term challenges.
The company's strategic focus on innovation, resource management, and portfolio diversification positions it for future success.
While facing legal and financial headwinds, Johnson & Johnson remains optimistic about its outlook for 2023 and beyond.
Increased guidance, product developments, and commitment to safety and innovation underscore the company's long-term growth potential.

Johnson & Johnson reports strong Q2 earnings and strategic growth plans

Johnson & Johnson showcased robust financial results in Q2, raising full-year guidance and highlighting growth in MedTech and Pharmaceuticals. Despite challenges from pricing pressures and litigation, the company remains focused on strategic opportunities and maintaining a strong market position. With a clear focus on innovation and growth, Johnson & Johnson is poised for continued success in the healthcare sector.

Johnson & Johnson posts strong Q3 results amidst growth strategies

Johnson & Johnson (JNJ) delivered robust Q3 results, showcasing growth in sales, earnings, and operational efficiency across key segments, positioning the company for future success.
While facing challenges from geopolitical factors, legal issues, and upcoming competition, JNJ's strategic strengths in acquisitions, innovation, and market presence offer avenues for sustained growth.
With a focus on key brands, pipeline advancements, and MedTech innovations, JNJ remains poised to meet revenue targets, navigate challenges, and capitalize on market opportunities in the coming years.

Johnson & Johnson reports robust 2023 performance and strategic growth outlook

Johnson & Johnson's strong 2023 performance in Innovative Medicine and MedTech drove operational sales growth. Despite inflationary pressures impacting margins, JNJ remains focused on enhancing shareholder returns and pursuing strategic M&A deals. Opportunities for growth in 2024 include new product launches and advancements in key focus areas.

Johnson & Johnson posts strong Q1 earnings, eyes growth opportunities

Johnson & Johnson's Q1 2024 earnings reflect solid performance across key segments, with a focus on innovation and strategic growth initiatives.
Despite challenges in certain segments, the company's proactive approach to restructuring and market dynamics positions it for future success.
Opportunities in Vision Care, Pulmonary Hypertension, and Orthopaedics underscore potential for sustained growth and market leadership.
Overall, Johnson & Johnson's diversified product portfolio and financial outlook support confidence in achieving growth targets for 2024.

Johnson & Johnson posts strong Q2 results, eyes growth opportunities

Johnson & Johnson delivered a robust performance in Q2 2024, driven by strong sales growth in both Innovative Medicine and MedTech segments, supported by strategic initiatives.
While facing challenges in certain markets and the need for continued innovation, the company's outlook remains positive with a solid guidance for the full year 2024.
By capitalizing on opportunities in key products and markets, Johnson & Johnson is well-positioned to navigate challenges and drive sustainable growth in the healthcare sector.

Johnson & Johnson reports robust Q3 earnings amidst legal challenges

Johnson & Johnson's Q3 2024 earnings call showcased strong financial performance, driven by growth in key segments and successful product launches. Despite facing challenges with talc litigation, the company remains focused on innovation, capital allocation, and resolving legal issues.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Disney

Morgan Stanley

Starbucks

"You've got to treat ugly moments like this one as buying opportunities," the "Mad Money" host said.

Jim Cramer picks 4 'buyable' stocks to snap up after ugly market days

AbbVie

Bristol-Myers

Merck

Pfizer

Seagen

Sanofi

AstraZeneca

Novartis

Roche Holding AG

Investors who are sweating the loss of patent protection for some of Big Pharma's top-selling drugs should relax.

Investors Need Not Be Alarmed by Drug Patent Expirations

Johnson & Johnson JNJ, -2.81% does not plan to update its COVID-19 vaccine, though other vaccine makers like Moderna Inc. MRNA, -2.86% , BioNTech SE BNTX, -2.69% and Pfizer Inc. PFE, -2.58% , and Novavax Inc. NVAX, -6.03% are already working on new versions that aim to better protection against the currently circulating strains of the virus. "The company will focus on supplying its COVID-19 vaccine in parts of the world where the pandemic remains an emergency and there is acute need," a J&J spokesperson told MarketWatch in an email on Tuesday.

J&J does not plan to update its COVID-19 vaccine

Coca-Cola

Altria

These dividend stocks could undoubtedly bring you a lifetime of passive income.

New to Dividend Stocks? Start by Buying These 3 Ultra-Safe Picks

BYD Company Limited

Visa

These Buffett stocks look primed for a bull run, so buy them while you still can.

Got $1,000? 3 Buffett Stocks to Buy Now and Hold Forever

Over the past decade, the stock has closely tracked the S&P 500.

Could Johnson & Johnson Stock Help You Retire A Millionaire?

Chevron

Essex Property Trust

Dividend Aristocrats tend to outperform during market downturns and crashes. An allocation towards these names can thus make sense from a risk perspective. Not all Dividend Aristocrats are created equal, however. Some are expensive today, while others are a way better value right now.

5 Dividend Aristocrats To Buy And 5 Dividend Aristocrats To Avoid

Costco

Intel

McDonald's

Tesla

Large-cap stocks to buy with the broad market correction. Stocks to buy and hold for the long-term for dividends and stock upside.

7 Large-Cap Stocks to Buy After the Next Big Correction

American Tower

Diageo

Ecolab

NIKE

Inflation, interest rate hikes, recessions. There's a lot to worry about right now.

7 Retirement Stocks to Buy After Age 30

McKesson

Their businesses are built for times like these.

3 Top Warren Buffett Stocks to Buy in This Bear Market

Alphabet

Home Depot

Illumina

Netflix

Public Storage

When you buy shares of stock, you become a partner in a business. Perhaps I'm stating the obvious, but I doubt all investors see their purchases that way.

10 Stocks to Buy When They're Down

J&J's (JNJ) Pharma unit is performing above market levels. Sales in the Consumer unit are being hurt by external supply constraints.

J&J's (JNJ) Stock Outperforms Industry YTD: Here's Why

Apple

JPMorgan Chase & Co

Mondelez

NVIDIA

Procter & Gamble

Walmart

Exxon Mobil

Bear markets often present the best investment opportunities. Consider the following strategies to profit in this 2022 bear market.

Bear Market 2022: Is There Anything Left to Invest In?

Mastercard

STORE Capital

Rapidly rising prices are no match for these highly profitable industry leaders.

5 Warren Buffett Stocks That Can Help You Crush Historically High Inflation

Johnson & Johnson (NYSE:JNJ ) Environmental, Social & Governance (ESG) Investor Update June 21, 2022 8:30 AM ET Company Participants Jessica Moore - Vice President of Investor Relations Joseph Wolk - Executive Vice President & Chief Financial Officer Anne Mulcahy - Independent Lead Director, Nominating and Corporate Governance Committee Chair Mark Weinberger - Independent Director, Regulatory Compliance Committee Chair Mary Beckerle - Independent Director, Science, Technology and Sustainability Committee Chair Joaquin Duato - Chief Executive Officer Matthew Orlando - Corporate Secretary and Worldwide Vice President, Corporate Governance Martin Fitchet - Head of Global Public Health Lauren Moore - Vice President, Global Community Impact Peter Fasolo - Executive Vice President, Chief Human Resource Officer Wanda Hope - Chief Diversity, Equity and Inclusion Officer Paulette Frank - Chief Sustainability Officer Dirk Brinckman - Chief Compliance Officer Carol Montandon - Chief Quality Officer Kristen Mulholland - Head of Human Resources, Global Total Rewards & Enterprise HR Conference Call Participants Louise Chen - Cantor Fitzgerald Lei Huang - Wells Fargo Rick Wise - Stifel Terence Flynn - Morgan Stanley Joshua Jennings - Cowen and Company Operator Please note that today's meeting may include forward-looking statements relating to, among other things, the company's future financial performance, product development, market position and business strategy and the anticipated separation of the company's Consumer Health business. You're cautioned not to rely on these statements, which are based on current expectations of future events using the information available as of today's date and are subject to certain risks and uncertainties that may cause the company's actual results to differ materially from those projected.

Johnson & Johnson (JNJ) Environmental, Social & Governance (ESG) Investor Update (Transcript)

The new Satellite Center will work to accelerate discovery research against flaviviruses, including dengue, which impacts 400 million people each year This effort will build on Johnson & Johnson's decade-long legacy and ongoing collaboration with Duke-NUS in early-stage dengue research The Satellite Center is the first Asia Pacific site in Johnson & Johnson's network of research collaborations aimed at addressing entrenched and emerging pandemic threats SINGAPORE , June 20, 2022 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) (the Company) today announced the launch of the new J&J Satellite Center for Global Health Discovery (Satellite Center) at Singapore's Duke-NUS Medical School, jointly established by Duke University and the National University of Singapore (NUS) as a graduate-entry medical school and research powerhouse. As the first of the J&J Centers for Global Health Discovery (J&J Centers) in the Asia-Pacific region, the Satellite Center at Duke-NUS aims to help drive new solutions to address flaviviruses, which disproportionately impact communities across the region, by bringing together the talent and expertise of the world's largest healthcare company with that of a leading academic institution.

Johnson & Johnson Opens First Satellite Center for Global Health Discovery in Asia Pacific at Duke-NUS to Advance Dengue Research

Abbott Labs

Amgen

With so much carnage in the stock market right now, investors are rushing to the exits trying to preserve what gains they have left. In a market-wide sell-off, stocks of all stripes get sold off, regardless of quality.

3 Oversold Health Care Stocks Set for a Rebound

Alnylam Pharmaceuticals

If you have the discipline to think long-term as an investor, this is the time to take advantage of the steep discounts on great biotechnology companies.

Seven reasons the beleaguered biotech sector is now a ‘buy'

News for Johnson & Johnson Stock (JNJ)